Avalo Therapeutics Balance Sheet
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics financial position
At the end of fiscal 2025, Avalo Therapeutics reported total assets of $116.5 million, down 22.7% from a year earlier against total liabilities of $33.4 million. Shareholders' equity stood at $83.0 million, or 71.3% of assets. The company held $15.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.14, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Avalo Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 15.86M | 134.55M | 7.42M | 13.17M | 54.59M | 18.92M | 3.61M | 10.65M | 2.47M | 5.13M |
| Short-Term Investments | 82.48M | 0 | — | — | — | — | — | — | — | — |
| Receivables | — | — | — | 0 | — | — | — | — | — | — |
| Inventory | — | — | 0 | 20.00K | 38.00K | 3.00K | 21.33K | 317.92K | 382.15K | 0 |
| Total Current Assets | 105.29M | 138.89M | 8.39M | 16.42M | 61.84M | 26.00M | 17.72M | 21.93M | 10.67M | 5.66M |
| Property, Plant & Equipment | — | — | — | — | — | — | 1.45M | 586.51K | 44.61K | 43.24K |
| Goodwill | 10.50M | 10.50M | 10.50M | 14.41M | 14.41M | 14.41M | 14.41M | 14.41M | 12.29M | 0 |
| Intangible Assets | — | — | — | 0 | 38.00K | 1.58M | 2.43M | 3.77M | 17.66M | 0 |
| Long-Term Investments | 0 | — | — | — | — | — | — | — | — | — |
| Total Assets | 116.46M | 150.73M | 20.99M | 33.37M | 80.21M | 43.76M | 36.11M | 70.25M | 42.81M | 5.77M |
| Accounts Payable | 137.00K | 283.00K | 446.00K | 2.88M | 3.37M | 2.57M | 2.08M | 1.45M | 1.30M | 1.01M |
| Short-Term Debt | — | — | — | — | — | — | — | 1.05M | 0 | 2.35M |
| Total Current Liabilities | 12.94M | 6.96M | 4.62M | 22.11M | 19.89M | 15.22M | 12.16M | 26.22M | 11.09M | 4.31M |
| Long-Term Debt | — | — | 0 | 13.49M | 32.83M | 0 | — | 14.33M | 0 | 0 |
| Total Liabilities | 33.41M | 17.70M | 13.69M | 44.28M | 57.13M | 19.19M | 15.11M | 49.34M | 14.95M | 5.56M |
| Shareholders' Equity | 83.05M | 133.03M | 7.30M | -10.91M | 23.08M | 24.56M | 21.00M | 20.91M | 27.86M | 207.00K |
| Retained Earnings | -448.52M | -370.26M | -335.13M | -303.82M | -262.17M | -177.79M | -114.29M | -98.22M | -58.17M | -70.04M |
| Total Debt | — | — | 0 | 13.49M | 32.83M | 0 | — | 15.38M | 0 | 2.35M |
| Net Cash (Debt) | 98.34M | 134.55M | 7.42M | -314.00K | 21.75M | 18.92M | 3.61M | -4.73M | 2.47M | 2.77M |
| Shares Outstanding | 18.51M | 10.47M | 801.75K | 39.29K | 9.40M | 75.00M | 44.38M | 40.80M | 31.27M | 9.43M |
This table shows 10 annual periods of Avalo Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AVTX's reporting calendar. What is a balance sheet?